DRG Epidemiology’s coverage of hereditary angioedema (HAE) comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the prevalence of HAE for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets of the United States, Europe, and Japan, and 10 years for the other countries covered in this report.

DRG Epidemiology’s HAE forecast will answer the following questions:

  • In developing countries, what impact will economic growth and development have on the number of people living with a diagnosis of HAE ?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of HAE over the forecast period?

All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

In addition to the total number of cases for each forecast year, DRG Epidemiology provides at least ten years of forecast data for the following HAE subpopulations:

  • HAE subtype.

Note: Coverage may vary by country.

Last updated: September 2018

Table of contents

  • Hereditary Angioedema - Epidemiology - Mature Markets Data
    • Introduction
      • Prevalence of Hereditary Angioedema per 100,000 Among People of All Ages in 2018 and 2038
      • Patient Flow Diagram for Hereditary Angioedema Across All Countries Under Study in 2018
      • Relative Sizes of the Factors Contributing to the Trend in Prevalent Cases of Hereditary Angioedema over the Next 20 Years
      • Analysis of Diagnosed Prevalent Cases of Hereditary Angioedema Across the Countries Under Study in 2018 by Subtype
    • Epidemiology Data
    • Methods
      • Diagnosed Prevalence
      • HAE Subtype
    • Reference Materials
      • Literature Review
        • Studies Included in the Analysis of Hereditary Angioedema
        • Studies Excluded from the Analysis of Hereditary Angioedema
      • Risk/Protective Factors
        • Risk/Protective Factors for Hereditary Angioedema
      • Bibliography

Author(s): Mudasir Khan, M.P.H.; Abey John, MPH

Mudasir works as an associate epidemiologist within the epidemiology team at Decision Resources Group. He specializes in developing epidemiological forecasts for multiple indications within the DRG syndicated portfolio.

Mudasir holds a masters in public health specializing in epidemiology from TISS, Mumbai.

Abey John is a medical graduate with a Master’s in Public Health and has been associated with DRG since September 2015. He works with a global team of epidemiologists in performing systematic reviews of assigned diseases and prepare forecast models for clients. He also is involved in producing analyses for pharmaceutical drug developers on the descriptive epidemiology of major drug indications in mature and developing markets and have an overall experience of three years working in different healthcare sectors across the country.

Prior to joining DRG, Abey had been working with Jhpiego (an affiliate of Johns Hopkins Medical University) in implementing Family Planning Health Programs in India with collaborating with the Government of India. He also has worked with a grassroots level NGO as a health team manager which worked for the benefit of the rural population living in the foothills of the Himalayas.